Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36 Page 37 Page 38 Page 39 Page 40 Page 41 Page 42 Page 43 Page 44Abstracts & Posters 10 Abstract Submission Timeline January 23, 2017 Abstract Submission site opens April 17, 2017 Abstract Submission site closes Mid-May 2017 Abstract notifications sent by email to first authors regarding decisions by the Annual Meeting Program Committee on the status of acceptance June 9, 2017 Deadline to submit Registration Form & Abstract Contract or to withdraw abstract(s) Areas of Abstract Submission • Absorption, Distribution, Metabolism and Elimination • Applications of Modeling and Simulation • Big Data • Biosimilars • Chronic Pain and Opioid Management • Clinical Pharmacokinetics and Pharmacodynamics • Clinical Pharmacology Education • Clinical Trials and Human Pharmacology • Counterfeit Drugs • Decision Making in Research and Development • Disease Management • Drug-induced Organ Injury • Drug Interactions • Effectiveness and Impact on Quality of Life • Emerging Technologies in Clinical Pharmacology • Experimental Pharmacology in In Vitro and In Vivo Studies • HIV/AIDS • Immunology/Immunotherapy • Infectious Diseases (Antibiotics/Vaccines) • Mechanism of Action • Model-based Drug Development • New and Adaptive Clinical Trial Designs • Novel Use of Antidepressants • Oncology • Orphan Drugs • Pediatrics • Pharmacoeconomics • Pharmacoepidemiology • Pharmacogenomics • Pharmacometrics • Precision Medicine as it Relates to Drug Development • Precision Medicine as it Relates to Patient Care • Regulatory Issues • Risk Management/Legal Issues • Safety and Efficacy • Special Populations • Therapeutic Drug Monitoring • Translational Medicine, Including Biomarkers and/or Imaging PRIMARY CRITERIA FOR ACCEPTANCE OF ABSTRACTS ARE: • Applicability to clinical pharmacology and translational medicine • Innovation and scientific merit • Relevance to ACCP’s mission ACCP accepts encore poster presentations; however, encores must be documented as such when the abstract is submitted. EACH ABSTRACT MUST CONTAIN: • A statement of purpose, innovation or hypothesis • Description of methods and materials • Data and results • Interpretation, conclusion and significance Instructions for Abstracts & Posters WHEN PREPARING YOUR POSTER FOR PRESENTATION AT THE ACCP ANNUAL MEETING, WE KINDLY ASK THAT YOU ADHERE TO THE FOLLOWING GUIDELINES: • All material should be legible from distances of at least three feet. • Presenter’s name must be underlined throughout the entire document. • For all authors, initial or first name must precede last name. • Institutional affiliation and city are required. • Ensure that the street address, zip code, degrees and grant support are NOT listed within the abstract. • Use only standard abbreviations. • All compounds that are designated by code must be identified adequately. • Do not indent the title. • Capitalize the first letter of trade names. • Nonproprietary (generic) names are required the first time a drug is mentioned, written in lower case letters. • Abstract is limited to approximately 350 words (2,780 characters, including spaces) which includes titles. One table is permitted; it will not be counted or applied to word limitations. • When using abbreviations for compounds, spell out in full the first mention, followed by the abbreviation in parentheses. Do not abbreviate compounds within the title of the abstract. • Special characters are permitted. • Important Size Limitations: No larger than the usable size of the poster board which is 45 inches tall and 67 inches wide. All posters will be mounted horizontally. Please note: Poster presenters have the sole obligation of ensuring that the information and spelling on all authors and content is accurate at the time of submission. ACCP holds no responsibility for corrections after publication of any materials related to the meeting. Emergin Alte Special Populations Big Data